PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1954303-0 1991 Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Galantamine 86-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 1914378-5 1991 The inhibition of acetylcholinesterase activity was closely correlated with the pharmacokinetics of galanthamine, a median maximal value of 53% being achieved by applying 10 mg galanthamine intravenously. Galantamine 100-112 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 1914378-5 1991 The inhibition of acetylcholinesterase activity was closely correlated with the pharmacokinetics of galanthamine, a median maximal value of 53% being achieved by applying 10 mg galanthamine intravenously. Galantamine 177-189 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 1954303-2 1991 Acetylcholinesterase activity was most effectively inhibited in all tissues by physostigmine, followed by tacrine and galanthamine. Galantamine 118-130 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 1954303-4 1991 In addition, the inhibition of acetylcholinesterase by galanthamine was similar in postmortem brain and brain cortical biopsies from patients submitted to brain-tumour removal, indicating that postmortem changes up to 28 h after death probably did not influence the measurement of acetylcholinesterase inhibition. Galantamine 55-67 acetylcholinesterase (Cartwright blood group) Homo sapiens 31-51 1926583-2 1991 Such reversible inhibitors as tacrine (of non-competition action), ambenonium (mixed action) and galanthamine (competitive type of action) decelerate the decarbamylation rate of acetylcholinesterase. Galantamine 97-109 acetylcholinesterase (Cartwright blood group) Homo sapiens 178-198 2355800-0 1990 Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Galantamine 54-66 acetylcholinesterase (Cartwright blood group) Homo sapiens 30-50 2355800-5 1990 In vivo, administration of galanthamine in a healthy volunteer and in a patient who underwent long-term treatment confirmed the selectivity of galanthamine for acetylcholinesterase. Galantamine 143-155 acetylcholinesterase (Cartwright blood group) Homo sapiens 160-180 33776997-3 2021 Galantamine, an acetylcholinesterase inhibitor and a cholinergic drug that is clinically-approved (for Alzheimer"s disease) has been implicated in neural cholinergic regulation of inflammation in several conditions characterized with immune and metabolic derangements. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-36 34971946-3 2022 The in vitro assessment of the synthesized compounds revealed that all of them showed significant activity (IC50 ranging from 0.42 to 1.296 microM) towards AChE compared to the standard drug, galantamine (IC50 = 1.142 +- 0.027 microM). Galantamine 192-203 acetylcholinesterase (Cartwright blood group) Homo sapiens 156-160 34299650-5 2021 When compared with the commercial anti-Alzheimer drug galanthamine, nitidine was as potent as galanthamine against hAChE and one order of magnitude more potent against hBuChE. Galantamine 94-106 acetylcholinesterase (Cartwright blood group) Homo sapiens 115-120 34628223-3 2021 Derivative 5f (IC50 = 0.86 +- 0.08 microM), 5g (IC50 = 1.05 +- 0.06 microM) and 5d (IC50 = 1.64 +- 0.06 microM) exhibited higher AChE inhibitory activity as compared to standard drug galantamine (IC50 = 2.15 +- 0.05 microM). Galantamine 183-194 acetylcholinesterase (Cartwright blood group) Homo sapiens 129-133 34664067-9 2021 The relative AChE inhibitory activities of jatrorrhizine, berberine and palmatine in the Coptidis Rhizoma sample were equal to that of 257.0, 2355 and 283.9 mug/mL of galanthamine, respectively. Galantamine 167-179 acetylcholinesterase (Cartwright blood group) Homo sapiens 13-17 34443482-7 2021 In silico study suggested the compounds preferred the peripheral anionic site (PAS) to the catalytic anionic site (CAS), which was different from AChE inhibitors (tacrine and galanthamine). Galantamine 175-187 acetylcholinesterase (Cartwright blood group) Homo sapiens 146-150 34132933-8 2021 Separately, the crystal structure of AChE in complex with (-)-galantamine was used to perform molecular docking calculations with the entire SistematX dataset. Galantamine 62-73 acetylcholinesterase (Cartwright blood group) Homo sapiens 37-41 34755546-6 2021 The selectivity for AChE over BuChE of compound 8e was approximately 17-times higher than donepezil and 26-times higher than galantamine. Galantamine 125-136 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-24 34363318-0 2021 Structural Fractal Analysis of the Active Site of Acetylcholinesterase in Complexes with Huperzine A, Galantamine, and Donepezil. Galantamine 102-113 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-70 34363318-1 2021 The fractal dimension (D) of the active site of hAChE in the unliganded state and as part of complexes with hyperzine A, galantamine, and donepezil is calculated using molecular interatomic-distance histograms. Galantamine 121-132 acetylcholinesterase (Cartwright blood group) Homo sapiens 48-53 35527546-0 2022 A Cobalt-Containing Compound as a Stronger Inhibitor than Galantamine to Inhibit Acetylcholinesterase Activity: A New Drug Candidate for Alzheimer"s Disease Treatment. Galantamine 58-69 acetylcholinesterase (Cartwright blood group) Homo sapiens 81-101 35630613-3 2022 The achieved success of plant-based natural drugs acting as AChE inhibitors, such as galantamine (GAL) from Galanthus genus and huperzine A from Huperzia serrate (approved drug in China), in the treatment of AD, and the fact that natural compounds (NCs) are considered as safer and less toxic compared to synthetic drugs, led us to screen the available NCs (almost 150,000) in the ZINC12 database for AChE inhibitory activity. Galantamine 85-96 acetylcholinesterase (Cartwright blood group) Homo sapiens 60-64 35630613-3 2022 The achieved success of plant-based natural drugs acting as AChE inhibitors, such as galantamine (GAL) from Galanthus genus and huperzine A from Huperzia serrate (approved drug in China), in the treatment of AD, and the fact that natural compounds (NCs) are considered as safer and less toxic compared to synthetic drugs, led us to screen the available NCs (almost 150,000) in the ZINC12 database for AChE inhibitory activity. Galantamine 98-101 acetylcholinesterase (Cartwright blood group) Homo sapiens 60-64 35563466-5 2022 As a case study, the inhibition of acetylcholinesterase by galantamine, a drug approved for the symptomatic treatment of Alzheimer"s disease, is reported. Galantamine 59-70 acetylcholinesterase (Cartwright blood group) Homo sapiens 35-55 35563466-7 2022 Re-examination of acetylcholinesterase inhibition by pre-steady state analysis of the reaction progress curves showed that the potency of galantamine has indeed been underestimated by a factor of ~100. Galantamine 138-149 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 35595404-2 2022 Current pharmacological treatment includes acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine; however, only one-third of patients respond to treatment. Galantamine 87-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 43-63 35098414-5 2022 Accumulated evidence reveals that Kv channels, which are broadly expressed in brain and possess crucial functions in modulating the neuronal activity, are inhibited by several acetylcholinesterase (AChE) inhibitors, such as tacrine, bis(7)-tacrine, donepezil and galantamine. Galantamine 263-274 acetylcholinesterase (Cartwright blood group) Homo sapiens 176-196 35462270-11 2022 The binding energies of the complexes, title compound-AChE, donepezil-AChE, and galantamine-AChE, were calculated to be -7.80, -10.41, and -8.16 kcal/mol, respectively. Galantamine 80-91 acetylcholinesterase (Cartwright blood group) Homo sapiens 92-96 35098414-5 2022 Accumulated evidence reveals that Kv channels, which are broadly expressed in brain and possess crucial functions in modulating the neuronal activity, are inhibited by several acetylcholinesterase (AChE) inhibitors, such as tacrine, bis(7)-tacrine, donepezil and galantamine. Galantamine 263-274 acetylcholinesterase (Cartwright blood group) Homo sapiens 198-202 33916760-8 2021 It was found that the selected compound was a powerful non-toxic AChE inhibitor, 68 times more active than GAL, and could serve as a lead molecule for further optimization and development. Galantamine 107-110 acetylcholinesterase (Cartwright blood group) Homo sapiens 65-69 5873635-0 1965 [Acetylcholinesterase and the bioelectrical activity of the brain under the action of eserine and galanthamine in animals with premesencephalic section of the brain]. Galantamine 98-110 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-21 33540879-8 2021 Donepezil and galantamine (DonGal) was synergistic for human AChE but antagonistic for tcAChE. Galantamine 14-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-65 32146656-6 2021 The obtained results indicate that compound 2 is the best acetylcholinesterase inhibitor with a low IC50 value comparable to that of the galantamine. Galantamine 137-148 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-78 33382027-3 2020 The crystal structure of galantamine bound human acetylcholinesterase (hAChE) has been reported; however, the inhibition mechanism of hAChE by galantamine is not well understood. Galantamine 143-154 acetylcholinesterase (Cartwright blood group) Homo sapiens 71-76 33382027-3 2020 The crystal structure of galantamine bound human acetylcholinesterase (hAChE) has been reported; however, the inhibition mechanism of hAChE by galantamine is not well understood. Galantamine 25-36 acetylcholinesterase (Cartwright blood group) Homo sapiens 71-76 33382027-3 2020 The crystal structure of galantamine bound human acetylcholinesterase (hAChE) has been reported; however, the inhibition mechanism of hAChE by galantamine is not well understood. Galantamine 25-36 acetylcholinesterase (Cartwright blood group) Homo sapiens 134-139 33382027-3 2020 The crystal structure of galantamine bound human acetylcholinesterase (hAChE) has been reported; however, the inhibition mechanism of hAChE by galantamine is not well understood. Galantamine 143-154 acetylcholinesterase (Cartwright blood group) Homo sapiens 134-139 33382027-4 2020 A Well-tempered metadynamics (WTMtD) simulation study has been performed with the crystal structure of galantamine bound hAChE. Galantamine 103-114 acetylcholinesterase (Cartwright blood group) Homo sapiens 121-126 33382027-6 2020 Such proton transfer process is lowered in the presence of galantamine due to the separation of catalytic triad inside the gorge of AChE as observed with WTMtD. Galantamine 59-70 acetylcholinesterase (Cartwright blood group) Homo sapiens 132-136 33382027-7 2020 A docking study has been performed to examine the ACh"s binding with the catalytic triad of galantamine bound hAChE. Galantamine 92-103 acetylcholinesterase (Cartwright blood group) Homo sapiens 110-115 33030113-2 2021 More recently, a novel series of 4-N-phenylaminoquinolines was synthesized and evaluated against AChE and BuChE in which one of the compounds displayed appreciable inhibition compared to the standard compound, galantamine. Galantamine 210-221 acetylcholinesterase (Cartwright blood group) Homo sapiens 97-101 33054569-3 2022 While acetylcholinesterase (AChE) inhibitors such as donepezil and galantamine are leading drugs in the symptomatic treatment of AD, new AChE inhibitors continue to be explored for improved potency and selectivity. Galantamine 67-78 acetylcholinesterase (Cartwright blood group) Homo sapiens 28-32 32717861-2 2020 GAL acts mainly as an inhibitor of the enzyme acetylcholinesterase (AChE). Galantamine 0-3 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-66 32470371-3 2020 The geranylated compounds, cowanin (13), cowagarcinone E (15), norcowanin (16) and cowanol (17) exhibited potent inhibitions against acetylcholinesterase (AChE) (IC50 0.33-1.09 muM) and butyrylcholinesterase (BChE) (IC50 0.048-1.84 muM), which were more active than the reference drug, galanthamine. Galantamine 286-298 acetylcholinesterase (Cartwright blood group) Homo sapiens 133-153 32470371-3 2020 The geranylated compounds, cowanin (13), cowagarcinone E (15), norcowanin (16) and cowanol (17) exhibited potent inhibitions against acetylcholinesterase (AChE) (IC50 0.33-1.09 muM) and butyrylcholinesterase (BChE) (IC50 0.048-1.84 muM), which were more active than the reference drug, galanthamine. Galantamine 286-298 acetylcholinesterase (Cartwright blood group) Homo sapiens 155-159 32759369-4 2020 Subsequent experiments demonstrated that 100% of NHPs pretreated with either dose of galantamine, challenged with soman, and posttreated with conventional antidotes survived 24 h. By contrast, given the same posttreatments, 0% and 40% of the NHPs pretreated, respectively, with vehicle and pyridostigmine bromide (1.2 mg/kg, oral), a peripherally acting reversible AChE inhibitor approved as pretreatment for military personnel at risk of exposure to soman, survived 24 h after the challenge. Galantamine 85-96 acetylcholinesterase (Cartwright blood group) Homo sapiens 365-369 32763546-3 2020 Galantamine is not only a reversible, competitive inhibitor of acetylcholinesterase but also a type I positive allosteric modulator of alpha7nACh receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-83 32874532-1 2020 Background: Acetylcholinesterase inhibitors (AChEis) including donepezil, galantamine and rivastigmine are used to treat Alzheimer"s disease (AD). Galantamine 74-85 acetylcholinesterase (Cartwright blood group) Homo sapiens 12-32 32454229-2 2020 The activity evaluation led to the discovery of seven compounds with potent anti-acetylcholinesterase activity with IC50 values of <=0.72 muM, superior to chelerythrine and standard drugs galantamine. Galantamine 188-199 acetylcholinesterase (Cartwright blood group) Homo sapiens 81-101 32717861-2 2020 GAL acts mainly as an inhibitor of the enzyme acetylcholinesterase (AChE). Galantamine 0-3 acetylcholinesterase (Cartwright blood group) Homo sapiens 68-72 32717861-4 2020 Here, we combine GAL core with CU fragments and design a combinatorial library of GAL-CU hybrids as dual-site binding AChE inhibitors. Galantamine 17-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 118-122 33488178-2 2020 Food and Drug Administration (FDA) approved drugs donepezil, rivastigmine, tacrine and galantamine are AChE inhibitors and in the treatment of Alzheimer"s disease (AD) these drugs are currently prescribed. Galantamine 87-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 103-107 31847089-1 2019 Alkaloids having acetylcholinesterase (AChE) inhibitory activity are commonly found in traditional Chinese medicine (TCM); for example, berberine from Coptis chinensis, galantamine from Lycoris radiata, and huperzine A from Huperzia serrata. Galantamine 169-180 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-37 31686175-6 2020 A low dose of galantamine was chosen to minimize acetylcholinesterase inhibition, which was verified in blood assays. Galantamine 14-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 49-69 31686175-10 2020 A trend toward RT reduction by galantamine correlated with acetylcholinesterase inhibition. Galantamine 31-42 acetylcholinesterase (Cartwright blood group) Homo sapiens 59-79 32414155-4 2020 The current AChE inhibitors (donepezil, rivastigmine, and galantamine) have short-acting mechanisms of action that result in dose-limiting toxicity and inadequate efficacy. Galantamine 58-69 acetylcholinesterase (Cartwright blood group) Homo sapiens 12-16 31978679-3 2020 Compounds 4ah and 4bh proved to be more potent than the standard drug tacrine, rivastigmine and galantamine for AChE inhibition activity with IC50 value between 0.055 +- 0.143 microM and 0.017 +- 0.02 microM respectively. Galantamine 96-107 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-116 31847089-1 2019 Alkaloids having acetylcholinesterase (AChE) inhibitory activity are commonly found in traditional Chinese medicine (TCM); for example, berberine from Coptis chinensis, galantamine from Lycoris radiata, and huperzine A from Huperzia serrata. Galantamine 169-180 acetylcholinesterase (Cartwright blood group) Homo sapiens 39-43 30956012-3 2019 Compound 11b showed significant inhibitory activities on AChE and BChE with IC50 values of 0.86 and 2.65 muM, respectively, a lot better than that of reference drug galanthamine. Galantamine 165-177 acetylcholinesterase (Cartwright blood group) Homo sapiens 57-61 31222828-9 2019 In particular, compound IX, having better activity than galantamine against acetylcholinesterase and butyrylcholinesterase enzymes, was visualized using molecular docking. Galantamine 56-67 acetylcholinesterase (Cartwright blood group) Homo sapiens 76-96 30101703-5 2019 Plant derived licensed drugs, Galantamine and Huperzine-A were studied extensively due to their AChE inhibitory action for mild to moderate cases of AD. Galantamine 30-41 acetylcholinesterase (Cartwright blood group) Homo sapiens 96-100 29697300-1 2019 Galantamine (Gnt) is a natural alkaloid inhibitor of acetylcholinesterase and is presently one of the most used drugs in the treatment against Alzheimer"s disease during both the initial and intermediate stages. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-73 29697300-1 2019 Galantamine (Gnt) is a natural alkaloid inhibitor of acetylcholinesterase and is presently one of the most used drugs in the treatment against Alzheimer"s disease during both the initial and intermediate stages. Galantamine 13-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-73 30673880-10 2019 There is a consensus on benefit of initiating any acetylcholinesterase inhibitor (ACHI: donepezil, rivastigmine, and galantamine) as a first line of treatment for psychosis in AD, as it may reduce and/or avoid the need for the use antipsychotics. Galantamine 117-128 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-70 30819081-1 2019 BACKGROUND: Although no effective treatment for the Alzheimer"s disease currently exist, some drugs acting as Acetylcholinesterase inhibitors, like galanthamine have positively affected such patients. Galantamine 148-160 acetylcholinesterase (Cartwright blood group) Homo sapiens 110-130 31315114-2 2019 To further optimize treatment, acetylcholinesterase inhibitors such as donepezil and galantamine have gained increased interest, though with conflicting results. Galantamine 85-96 acetylcholinesterase (Cartwright blood group) Homo sapiens 31-51 30343499-3 2018 Drugs, such as tacrine, rivastigmine, donepezil, and galantamine are known as acetylcholinesterase inhibitors. Galantamine 53-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-98 29926988-2 2018 Galantamine, an acetylcholinesterase inhibitor, may reduce cigarette smoking in otherwise healthy treatment-seeking smokers. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-36 30643787-4 2018 Galantamine is an acetylcholinesterase inhibitor that is also a positive allosteric modulator at the alpha4beta2 and alpha7nACh receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 30079554-3 2018 Monophenyl (16-18) indenoquinolines significantly inhibited the AChE and BChE enzymes in ranges of IC50 37-57 nM and 84-93 nM, respectively, compared with their starting materials 15a-c and reference compounds (galanthamine and tacrine). Galantamine 211-223 acetylcholinesterase (Cartwright blood group) Homo sapiens 64-68 29723743-3 2018 Most of the synthesized compounds showed good inhibitory activity, among them, compounds 4d and 4g displayed highest potency against AChE (IC50 1.88 and 1.98 muM), and BChE (IC50 18.32 and 10.21 muM) enzyme, respectively than the standard drug, galanthamine. Galantamine 245-257 acetylcholinesterase (Cartwright blood group) Homo sapiens 133-137 29044771-10 2018 Galanthamine, galanthamine N-oxide and powelline should be the most prominent inhibitors of substrate accommodation in the active site of the Torpedo californica AChE (TcAChE), hAChE and hBChE enzymes. Galantamine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 162-166 29635172-2 2018 In the present study, a surface plasmon resonance (SPR)-based assay was developed and employed to investigate interactions between human recombinant AChE (hAChE) and four known ligands: galantamine, tacrine, donepezil and edrophonium. Galantamine 186-197 acetylcholinesterase (Cartwright blood group) Homo sapiens 149-153 29655025-7 2018 Molecular docking studies indicated that the binding mode of the compound 5f share common characteristics with the galantamine/donepezil-AChE complexes. Galantamine 115-126 acetylcholinesterase (Cartwright blood group) Homo sapiens 137-141 28974110-3 2018 Three acetylcholinesterase inhibitors (ACHEIs) have been approved for AD: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). Galantamine 135-143 acetylcholinesterase (Cartwright blood group) Homo sapiens 6-26 29570959-3 2018 Galantamine not only is an acetylcholinesterase inhibitor but has a dual mode of action as a alpha-7nACh receptor modulator as well. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 27-47 28711758-1 2017 In this report we assessed by docking and molecular dynamics the binding mechanisms of three FDA-approved Alzheimer drugs, inhibitors of the enzyme acetylcholinesterase (AChE): donepezil, galantamine and rivastigmine. Galantamine 188-199 acetylcholinesterase (Cartwright blood group) Homo sapiens 170-174 29286595-1 2018 OBJECTIVE: To examine whether galantamine, a cognitive-enhancing medication that is both acetylcholinesterase inhibitor and agonist at nicotinic acetylcholine receptors, is effective at improving cocaine use outcomes and cognitive functioning, alone and in combination with computerized cognitive behavioral therapy (CBT). Galantamine 30-41 acetylcholinesterase (Cartwright blood group) Homo sapiens 89-109 28374576-0 2017 Docking-based design and synthesis of galantamine-camphane hybrids as inhibitors of acetylcholinesterase. Galantamine 38-49 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-104 28374576-1 2017 Galantamine (GAL) as an acetylcholinesterase inhibitor (AChEI) is among the main drugs approved for the treatment of Alzheimer"s disease. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-44 28374576-1 2017 Galantamine (GAL) as an acetylcholinesterase inhibitor (AChEI) is among the main drugs approved for the treatment of Alzheimer"s disease. Galantamine 13-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-44 30023627-4 2017 The activities of 1 and 5 were comparable to those of galantamine, a clinically used AchE inhibitor. Galantamine 54-65 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-89 27900576-1 2017 Galantamine hydrobromide and (-)huperzine A, centrally active reversible acetylcholinesterase inhibitors, are potentially superior to the current standard, pyridostigmine bromide, as a pretreatment for organophosphorus chemical warfare nerve agent intoxication. Galantamine 0-24 acetylcholinesterase (Cartwright blood group) Homo sapiens 73-93 28724799-3 2017 The aim of this study was to assess the effects of galantamine, a centrally acting acetylcholinesterase inhibitor with antiinflammatory properties, on markers of inflammation implicated in insulin resistance and cardiovascular risk, and other metabolic and cardiovascular indices in subjects with MetS. Galantamine 51-62 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-103 27900576-3 2017 Although both galantamine and huperzine shared a similar time course profile for acetylcholinesterase inhibition, huperzine was 88 times more potent than galantamine. Galantamine 14-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 81-101 27900576-4 2017 The dose for 50% acetylcholinesterase inhibition (ID50) was 4.1 ug/kg for huperzine, 362 ug/kg for galantamine, and 30.9 ug/kg for pyridostigmine. Galantamine 99-110 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-37 27900576-6 2017 Huperzine and pyridostigmine were devoid of behavioral toxicity, whereas galantamine was behaviorally toxic at doses producing peak acetylcholinesterase inhibition of about 50% and higher. Galantamine 73-84 acetylcholinesterase (Cartwright blood group) Homo sapiens 132-152 28458525-2 2017 Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique cholinesterase inhibitor with both AChE and butyrylcholinesterase (BuChE; EC 3.1.1.8) inhibitory activity. Galantamine 21-32 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-78 28458525-2 2017 Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique cholinesterase inhibitor with both AChE and butyrylcholinesterase (BuChE; EC 3.1.1.8) inhibitory activity. Galantamine 21-32 acetylcholinesterase (Cartwright blood group) Homo sapiens 80-84 30183230-2 2017 Currently, drugs that are used symptomatically in the treatment of AD include acetylcholinesterase inhibitors (AChEIs) (rivastigmine, galantamine, donepezil) and N-methyl D-aspartate (NMDA) receptor antagonist (memantine). Galantamine 134-145 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-98 28338634-8 2017 Part of this work was the elimination of reversible inhibitors represented by galantamine from the active site of AChE. Galantamine 78-89 acetylcholinesterase (Cartwright blood group) Homo sapiens 114-118 28338634-9 2017 For this purpose, we used a lower pH to get the original activity of AChE after inhibition by galantamine. Galantamine 94-105 acetylcholinesterase (Cartwright blood group) Homo sapiens 69-73 27681239-6 2016 In addition, they showed acetylcholinesterase inhibition activity and some of them presented activity superior to that of the standard drug galantamine. Galantamine 140-151 acetylcholinesterase (Cartwright blood group) Homo sapiens 25-45 27914796-4 2017 Among the newly synthesized compounds, 5h, 9h, 9j, and 9p displayed higher AChE enzyme inhibitory activities than the standard drug, galantamine, with IC50 values of 0.83, 0.98, and 0.73muM, respectively. Galantamine 133-144 acetylcholinesterase (Cartwright blood group) Homo sapiens 75-79 27793617-3 2016 Galanthamine is an acetylcholinesterase inhibitor (AChEI) used to symptomatic treatment of Alzheimers disease (AD). Galantamine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-39 26260334-0 2015 Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 75-95 27505087-3 2016 Another derivative displayed a similar activity to that of reference drug (galanthamine) for inhibition of AChE and BChE. Galantamine 75-87 acetylcholinesterase (Cartwright blood group) Homo sapiens 107-111 30549626-2 2016 Among the many Amaryllidaceae compounds, galanthamine has been given a great amount of attention due to the fact that it possesses potent acetylcholinesterase inhibitory activity. Galantamine 41-53 acetylcholinesterase (Cartwright blood group) Homo sapiens 138-158 26833890-4 2016 Among them, 3-bromobenzylamide derivative 4m exhibited the best acetylcholinesterase inhibitory activity with IC50 value of 13 +- 1.4 nm which is 51-fold superior to galantamine, a reference drug. Galantamine 166-177 acetylcholinesterase (Cartwright blood group) Homo sapiens 64-84 27492242-0 2016 Docking-based Design of Galantamine Derivatives with Dual-site Binding to Acetylcholinesterase. Galantamine 24-35 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-94 27069875-2 2016 Galantamine is an acetylcholinesterase inhibitor and a positive allosteric modulator of the alpha7 nicotinic receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 27581632-3 2016 All compounds displayed considerable AChE and BuChE inhibitory activity and some of the compounds manifested remarkable anti-AChE activity compared to the reference compound, galantamine. Galantamine 175-186 acetylcholinesterase (Cartwright blood group) Homo sapiens 125-129 26833077-6 2016 RESULTS: Among them, 3j displayed higher inhibitory activities than reference drug, galanthamine, with IC50 values of 2.05 and 5.77 microM, for AChE and BChE, respectively. Galantamine 84-96 acetylcholinesterase (Cartwright blood group) Homo sapiens 144-148 27222217-4 2016 To fill this apparent gap, we used electroencephalography (EEG) and a within-subject design in healthy humans who either received the acetylcholinesterase inhibitor galantamine (8mg) or a placebo before they performed a Sternberg WM paradigm. Galantamine 165-176 acetylcholinesterase (Cartwright blood group) Homo sapiens 134-154 26795115-3 2016 Particularly, the AChE inhibition potency of compound 5k (IC50 1.9muM) was even 5-fold higher than that of galantamine. Galantamine 107-118 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-22 26588065-2 2016 In vitro studies revealed that most of these compounds exhibited high inhibitory activity on acetylcholinesterase (AChE), with IC50 values ranging from 0.003 to 0.357 muM which is 2-220 folds more potent than the positive control, galantamine. Galantamine 231-242 acetylcholinesterase (Cartwright blood group) Homo sapiens 93-113 26588065-2 2016 In vitro studies revealed that most of these compounds exhibited high inhibitory activity on acetylcholinesterase (AChE), with IC50 values ranging from 0.003 to 0.357 muM which is 2-220 folds more potent than the positive control, galantamine. Galantamine 231-242 acetylcholinesterase (Cartwright blood group) Homo sapiens 115-119 26588065-3 2016 Their inhibition selectivity against AChE over butyrylcholinesterase (BuChE) has increased about 194 fold compared with galantamine. Galantamine 120-131 acetylcholinesterase (Cartwright blood group) Homo sapiens 37-41 28635795-3 2016 To overcome the cholinergic insufficiency, acetylcholinesterase inhibitors (rivastigmine, donepezil and galantamine) are primarily used. Galantamine 104-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 43-63 26260334-3 2015 In the present study, 41 galantamine derivatives with known acetylcholinesterase inhibitory activities expressed as IC50 were selected from the literature and docked into a recombinant human acetylcholinesterase by GOLD. Galantamine 25-36 acetylcholinesterase (Cartwright blood group) Homo sapiens 60-80 26260334-3 2015 In the present study, 41 galantamine derivatives with known acetylcholinesterase inhibitory activities expressed as IC50 were selected from the literature and docked into a recombinant human acetylcholinesterase by GOLD. Galantamine 25-36 acetylcholinesterase (Cartwright blood group) Homo sapiens 191-211 27490385-1 2015 A training set of 22 synthetic galantamine derivatives binding to acetylcholinesterase was docked by GOLD and the protocol was optimized in terms of scoring function, rigidity/flexibility of the binding site, presence/absence of a water molecule inside and radius of the binding site. Galantamine 31-42 acetylcholinesterase (Cartwright blood group) Homo sapiens 66-86 27490385-4 2015 The derived relationship was used to analyze the interactions between galantamine derivatives and AChE. Galantamine 70-81 acetylcholinesterase (Cartwright blood group) Homo sapiens 98-102 25712639-4 2015 Currently available treatments i.e. acetylcholinesterase inhibitors (rivastigmine, galantamine, donepezil) and N-methyl d-aspartate receptor antagonist (memantine) contribute minimal impact on the disease and target late aspects of the disease. Galantamine 83-94 acetylcholinesterase (Cartwright blood group) Homo sapiens 36-56 25998147-2 2015 National guidelines recommend treatment with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) or the N-Methyl-D-Aspartate antagonist (memantine) to reduce cognitive symptoms. Galantamine 89-100 acetylcholinesterase (Cartwright blood group) Homo sapiens 45-65 26264921-5 2015 Currently, acetylcholinesterase (AChE) inhibitors, such as donepezil, rivastigmine and galantamine are used to treat mild to moderate AD. Galantamine 87-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 11-31 26455564-4 2015 The mostly used therapy of Alzheimer disease is based on enhancing cholinergic function using inhibitors of acetylcholinesterase like rivastigmine, donepezil or galantamine. Galantamine 161-172 acetylcholinesterase (Cartwright blood group) Homo sapiens 108-128 26264921-5 2015 Currently, acetylcholinesterase (AChE) inhibitors, such as donepezil, rivastigmine and galantamine are used to treat mild to moderate AD. Galantamine 87-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 33-37 24774720-5 2014 We propose that oral form acetylcholinesterase inhibitors (donepezil, galantamine and rivastigmine) also posses the effect of inhibiting GABA receptors, and act as indirect antagonist, to be applied in the rapid detoxification treatment of BZDs and Z-drug dependence. Galantamine 70-81 acetylcholinesterase (Cartwright blood group) Homo sapiens 26-46 25462993-2 2014 Among the newly synthesized compounds, 5f, 5h and 7j displayed higher AChE enzyme inhibitory activities than standard drug, galanthamine, with IC50 values of 1.88, 2.05 and 2.03muM, respectively. Galantamine 124-136 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-74 24852273-4 2014 These strategies have been applied in the present case to the AChE inhibitor galantamine with the aim of alleviating adverse effects observed with cholinergic AD treatment. Galantamine 77-88 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-66 23307638-5 2014 The acetylcholinesterase inhibitor galantamine (8 mg), in contrast, reversed RS into repetition enhancement, showing no relationship to subsequent recognition memory. Galantamine 35-46 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 25202788-5 2014 In this connection, the efficacy of acetylcholinesterase inhibitors: galantamine (reminil),neuromidin, rivastigmine in the treatment of PD patients with dementia is discussed. Galantamine 69-80 acetylcholinesterase (Cartwright blood group) Homo sapiens 36-56 24694376-2 2014 Most of them showed comparable effects in inhibition of AChE, especially compound 6b which exhibited activity with IC50 value 1.17 microM, as strong as galanthamine. Galantamine 152-164 acetylcholinesterase (Cartwright blood group) Homo sapiens 56-60 23782591-1 2013 BACKGROUND: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer"s disease (AD). Galantamine 104-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 25-45 23618168-1 2013 Application to acetylcholinesterase inhibitor galantamine and its determination in pharmaceuticals and human urine. Galantamine 46-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 15-35 23618168-5 2013 The method developed is applied to the acetylcholinesterase inhibitor galantamine, using an acetylcholine-selective electrode. Galantamine 70-81 acetylcholinesterase (Cartwright blood group) Homo sapiens 39-59 24081314-2 2013 The acetylcholinesterase inhibitors donepezil, rivastigmine, and galantamine and the NMDA-receptor antagonist memantine have produced modest but apparently persistent improvements in cognition, activities of daily living, and behavior in patients with disease severity ranging from mild to severe. Galantamine 65-76 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 23602518-2 2013 Among the pyridopyrimidine derivatives, 7e and 7l displayed 2.5- and 1.5-fold higher enzyme inhibitory activities against AChE as compared to standard drug, galanthamine, with IC50 of 0.80 and 1.37 muM, respectively. Galantamine 157-169 acetylcholinesterase (Cartwright blood group) Homo sapiens 122-126 23408070-4 2013 Donepezil, galantamine and rivastigmine are acetylcholinesterase inhibitors with different pharmacodynamic and pharmacokinetic profiles. Galantamine 11-22 acetylcholinesterase (Cartwright blood group) Homo sapiens 44-64 23408070-5 2013 Donepezil inhibits selectively the acetylcholinesterase and has a long elimination half-life (t(1/2)) of 70 h. Galantamine is also a selective acetylcholinesterase inhibitor, but also modulates presynaptic nicotinic receptors. Galantamine 111-122 acetylcholinesterase (Cartwright blood group) Homo sapiens 35-55 23408070-5 2013 Donepezil inhibits selectively the acetylcholinesterase and has a long elimination half-life (t(1/2)) of 70 h. Galantamine is also a selective acetylcholinesterase inhibitor, but also modulates presynaptic nicotinic receptors. Galantamine 111-122 acetylcholinesterase (Cartwright blood group) Homo sapiens 143-163 22391555-7 2013 The use of AChE-ICER in the ligands recognition assay was validated by evaluation of four known reversible inhibitors (galanthamine, tacrine, propidium, and rivastigmine), and the same order of inhibitory potencies described in the literature was found. Galantamine 119-131 acetylcholinesterase (Cartwright blood group) Homo sapiens 11-15 23330848-4 2013 The assay method was validated using the reference AChE inhibitors tacrine and galanthamine. Galantamine 79-91 acetylcholinesterase (Cartwright blood group) Homo sapiens 51-55 23229229-3 2013 AChE inhibitors such as rivastigmine, galantamine, physostigmine and huperzine are obtained from plants, indicating that plants can serve as a potential source for novel AChE inhibitors. Galantamine 38-49 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 22931533-2 2013 Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 41-61 22931533-2 2013 Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-67 22931533-3 2013 The structurally diverse opioids codeine and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development. Galantamine 61-72 acetylcholinesterase (Cartwright blood group) Homo sapiens 135-139 23085657-3 2012 Compound 7f was found to be more selective than galanthamine in inhibiting AChE and it showed a moderate selectivity index. Galantamine 48-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 75-79 24092978-1 2013 OBJECTIVE: While acetylcholinesterase inhibitors, such as donepezil, galantamine, and rivastig-mine, are beneficial in treating behavioral symptoms of patients with Alzheimer"s disease (AD), their dose-limiting effects include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. Galantamine 69-80 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-37 23033965-2 2012 The compounds were designed by taking advantage of the crystal structures of acetylcholinesterase (AChE) in complex with galantamine derivatives. Galantamine 121-132 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-97 23033965-2 2012 The compounds were designed by taking advantage of the crystal structures of acetylcholinesterase (AChE) in complex with galantamine derivatives. Galantamine 121-132 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-103 22972560-9 2012 The comparison between the cluster calculations and the crystallographic observations in galanthamine-AChE co-crystals allows the validation of the theoretical methodology. Galantamine 89-101 acetylcholinesterase (Cartwright blood group) Homo sapiens 102-106 22972560-10 2012 In particular, the positions of several water molecules appearing as strongly conserved in galanthamine-AChE co-crystals are predicted by the calculations. Galantamine 91-103 acetylcholinesterase (Cartwright blood group) Homo sapiens 104-108 22972560-12 2012 Our study provides relevant information for a rational drug design of galanthamine based AChE inhibitors. Galantamine 70-82 acetylcholinesterase (Cartwright blood group) Homo sapiens 89-93 22539182-7 2012 Pharmacological studies showed that the complexes present a moderate inhibition of AChE with an IC(50) of 21 mumol L(-1) (referred to risvagtini, IC(50) 181 mumol L(-1) and galantamine IC(50) 0.006 mumol L(-1)) with no appreciable cytotoxicity toward to the HeLa cells (50% cell viability at 925 mumol L(-1)). Galantamine 173-184 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-87 21707398-2 2011 One pharmacological approach is to restore acetylcholine level by inhibiting acetylcholinesterase (AChE) with reversible inhibitors, such as galanthamine, thus helping to improve the cognitive symptoms of the disease. Galantamine 141-153 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-97 22211487-0 2012 Galantamine-based hybrid molecules with acetylcholinesterase, butyrylcholinesterase and gamma-secretase inhibition activities. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 22211487-4 2012 Strikingly, two of the galantamine amides that displayed low activity towards acetylcholinesterase exhibited the highest inhibitory potency towards butyrylcholinesterase (106 to 133 times more active than galantamine). Galantamine 23-34 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-98 23233806-2 2012 Galantamine is an acetylcholinesterase inhibitor that may also act via allosteric modulation of nicotinic acetylcholine receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 20880294-4 2011 RESULTS: Donepezil and galantamine groups showed a significant increase in CSF AChE activity at follow-up, while no changes for BChE activity were observed; in donepezil group, a positive correlation between plasma concentration and AChE activity was documented. Galantamine 23-34 acetylcholinesterase (Cartwright blood group) Homo sapiens 79-83 20880294-4 2011 RESULTS: Donepezil and galantamine groups showed a significant increase in CSF AChE activity at follow-up, while no changes for BChE activity were observed; in donepezil group, a positive correlation between plasma concentration and AChE activity was documented. Galantamine 23-34 acetylcholinesterase (Cartwright blood group) Homo sapiens 233-237 21621811-3 2011 The main class of medicines which are applied in AD is acetylcholinesterase inhibitors (AChEIs) like tacrine, donepezil, galantamine and rivastigmine that do not contribute to significant and long-term improvement in cognitive and behavioural functions. Galantamine 121-132 acetylcholinesterase (Cartwright blood group) Homo sapiens 55-75 21707398-2 2011 One pharmacological approach is to restore acetylcholine level by inhibiting acetylcholinesterase (AChE) with reversible inhibitors, such as galanthamine, thus helping to improve the cognitive symptoms of the disease. Galantamine 141-153 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-103 20851778-1 2011 UNLABELLED: Binding energy calculations of huperzine A (HUP A) and galanthamine (GAL) to the binding pocket of the acetylcholinesterase enzyme (AChE) were studied. Galantamine 67-79 acetylcholinesterase (Cartwright blood group) Homo sapiens 115-142 21594999-4 2011 Treatment with the NChR allosteric modulator and acetylcholinesterase (AChE) inhibitor, galantamine, led to a dramatic decline in the frequency and intensity of rage outbursts, suggesting that enhancement of alpha7 NChR function can ameliorate 15q13.3DS-associated rage outbursts. Galantamine 88-99 acetylcholinesterase (Cartwright blood group) Homo sapiens 49-69 21594999-4 2011 Treatment with the NChR allosteric modulator and acetylcholinesterase (AChE) inhibitor, galantamine, led to a dramatic decline in the frequency and intensity of rage outbursts, suggesting that enhancement of alpha7 NChR function can ameliorate 15q13.3DS-associated rage outbursts. Galantamine 88-99 acetylcholinesterase (Cartwright blood group) Homo sapiens 71-75 20851778-1 2011 UNLABELLED: Binding energy calculations of huperzine A (HUP A) and galanthamine (GAL) to the binding pocket of the acetylcholinesterase enzyme (AChE) were studied. Galantamine 67-79 acetylcholinesterase (Cartwright blood group) Homo sapiens 144-148 20851778-1 2011 UNLABELLED: Binding energy calculations of huperzine A (HUP A) and galanthamine (GAL) to the binding pocket of the acetylcholinesterase enzyme (AChE) were studied. Galantamine 81-84 acetylcholinesterase (Cartwright blood group) Homo sapiens 115-142 20851778-1 2011 UNLABELLED: Binding energy calculations of huperzine A (HUP A) and galanthamine (GAL) to the binding pocket of the acetylcholinesterase enzyme (AChE) were studied. Galantamine 81-84 acetylcholinesterase (Cartwright blood group) Homo sapiens 144-148 20655346-3 2010 Galantamine is an acetylcholinesterase (AChE) inhibitor widely used for patients with AD. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 21168544-2 2011 The capability of IMS in the determination of enzyme kinetics and inhibition studies by the analysis of substrate depletion and/or product formation using only a few microliters of solution has been successfully demonstrated on the example of acetylcholine hydrolysis catalyzed by acetylcholinesterase (AChE) and inhibited by neostigmine and galanthamine. Galantamine 342-354 acetylcholinesterase (Cartwright blood group) Homo sapiens 281-301 21168544-2 2011 The capability of IMS in the determination of enzyme kinetics and inhibition studies by the analysis of substrate depletion and/or product formation using only a few microliters of solution has been successfully demonstrated on the example of acetylcholine hydrolysis catalyzed by acetylcholinesterase (AChE) and inhibited by neostigmine and galanthamine. Galantamine 342-354 acetylcholinesterase (Cartwright blood group) Homo sapiens 303-307 20655346-3 2010 Galantamine is an acetylcholinesterase (AChE) inhibitor widely used for patients with AD. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-44 20452337-2 2010 Several AChE inhibitors, e.g. rivastigmine, galantamine and huperzine are originating from plants, suggesting that herbs could potentially serve as sources for novel AChE inhibitors. Galantamine 44-55 acetylcholinesterase (Cartwright blood group) Homo sapiens 8-12 20452337-2 2010 Several AChE inhibitors, e.g. rivastigmine, galantamine and huperzine are originating from plants, suggesting that herbs could potentially serve as sources for novel AChE inhibitors. Galantamine 44-55 acetylcholinesterase (Cartwright blood group) Homo sapiens 166-170 20193764-2 2010 Of known interventions, psychopharmacology provides readily available options, such as the anti-dementia drugs, e.g. acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Galantamine 161-172 acetylcholinesterase (Cartwright blood group) Homo sapiens 117-137 19969445-2 2010 Galanthamine, an important alkaloid isolated from the Amaryllidaceae family, is approved for the pharmacological treatment of Alzheimer"s disease (AD) and acts by inhibiting the acetylcholinesterase (AChE) activity. Galantamine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 178-198 19969445-2 2010 Galanthamine, an important alkaloid isolated from the Amaryllidaceae family, is approved for the pharmacological treatment of Alzheimer"s disease (AD) and acts by inhibiting the acetylcholinesterase (AChE) activity. Galantamine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 200-204 19969445-3 2010 In the present study, Ellman"s method was used to verify the inhibition of AChE activity of some isoquinolines alkaloids such as galanthamine, montanine, hippeastrine and pretazettine. Galantamine 129-141 acetylcholinesterase (Cartwright blood group) Homo sapiens 75-79 19969445-4 2010 At the concentrations 1mM, 500 microm and 100 microm, galanthamine presented an AChE inhibition higher than 90%. Galantamine 54-66 acetylcholinesterase (Cartwright blood group) Homo sapiens 80-84 20562785-2 2010 She was diagnosed with non-familial early-onset Alzheimer"s Disease (EOAD) and started on 8mg daily of the acetylcholinesterase inhibitor Galantamine. Galantamine 138-149 acetylcholinesterase (Cartwright blood group) Homo sapiens 107-127 20737911-2 2010 Alkaloids, such as physostigmine, galanthamine, and huperzine A, play an important role as AChE inhibitors. Galantamine 34-46 acetylcholinesterase (Cartwright blood group) Homo sapiens 91-95 19103181-1 2009 Galantamine is an acetylcholinesterase inhibitor and memantine is a non competitive antagonist of NMDA receptors that are being used to treat Alzheimer"s disease (AD) patients. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 19596285-6 2009 The inhibitory profiles of the compounds have been compared with standard AChE inhibitor galanthamine. Galantamine 89-101 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-78 20046396-3 2009 Therefore, we investigated the alterations in stress hormones such as cortisol and dehydroepiandrosterone sulfate (DHEAS) in CFS patients before and after 4-week administration of galantamine hydrobromide, a selective acetylcholinesterase inhibitor, and aimed to investigate whether there are any relationships between the probable hormonal changes and cholinergic treatment. Galantamine 180-204 acetylcholinesterase (Cartwright blood group) Homo sapiens 218-238 17379359-1 2008 The effect of galantamine treatment on cortical acetylcholinesterase (AChE) activity and nicotinic receptor binding was investigated by positron emission tomography (PET) in 18 patients with mild Alzheimer"s disease (AD) in relation to galantamine concentration and the patients" cognitive performances. Galantamine 14-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 48-68 18803156-3 2008 CASE REPORTS: Four patients with CADASIL and dementia were treated with the acetylcholinesterase inhibitor galantamine and we assessed cognitive, behavioral, functional and the caregiver burden aspects. Galantamine 107-118 acetylcholinesterase (Cartwright blood group) Homo sapiens 76-96 19199870-8 2009 Galantamine decreased AChE activity by 2.1% and BuChE activity by 0.5%, but increased AChE protein levels by 51.2% and BuChE protein levels by 10.5%. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 22-26 19199870-8 2009 Galantamine decreased AChE activity by 2.1% and BuChE activity by 0.5%, but increased AChE protein levels by 51.2% and BuChE protein levels by 10.5%. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 86-90 19199870-11 2009 Changes in mean AChE-Readthrough/Synaptic ratios, which might reflect underlying neurodegenerative processes, were 1.4, 0.6, and 0.4 for rivastigmine, donepezil and galantamine, respectively. Galantamine 165-176 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-20 19170055-1 2009 A simple and sensitive MEKC with UV detection was developed and validated for the simultaneous determination of acetylcholinesterase inhibitors including galantamine, rivastigmine and major metabolite NAP 226-90 in plasma. Galantamine 154-165 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-132 18789720-5 2008 The half maximal inhibitory concentration (IC(50)) value of galantamine obtained for AChE was 2.39 micromol L(-1). Galantamine 60-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-89 18550339-2 2008 Galantamine is an acetylcholinesterase inhibitor that acts as a positive allosteric modulator of nicotine acetylcholine receptors including both the alpha4beta2 and alpha7 subunits. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 17379359-1 2008 The effect of galantamine treatment on cortical acetylcholinesterase (AChE) activity and nicotinic receptor binding was investigated by positron emission tomography (PET) in 18 patients with mild Alzheimer"s disease (AD) in relation to galantamine concentration and the patients" cognitive performances. Galantamine 14-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-74 17379359-5 2008 Inhibition (30-40%) of cortical AChE activity was observed after 3 weeks to 12 months of galantamine treatment. Galantamine 89-100 acetylcholinesterase (Cartwright blood group) Homo sapiens 32-36 17379359-9 2008 In conclusion, galantamine caused sustained AChE inhibition for up to 12 months. Galantamine 15-26 acetylcholinesterase (Cartwright blood group) Homo sapiens 44-48 18042006-3 2007 The acetylcholinesterase inhibitors used to treat AD patients at present are donepezil, rivastigmine and galantamine. Galantamine 105-116 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 18191456-1 2008 Galantamine, an acetylcholinesterase inhibitor used to enhance memory in AD patients by acetylcholinesterase inhibition, has been tested for its protective properties on an in vitro model of H(2)O(2)-induced oxidative stress. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-36 18191456-1 2008 Galantamine, an acetylcholinesterase inhibitor used to enhance memory in AD patients by acetylcholinesterase inhibition, has been tested for its protective properties on an in vitro model of H(2)O(2)-induced oxidative stress. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 88-108 18191456-7 2008 Galantamine also concentration-dependently inhibited AChE activity (28-88%) in H(2)O(2)-SK-N-SH cells after 24h. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-57 17196712-0 2008 Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Galantamine 107-118 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 17196712-1 2008 The relationship between acetylcholinesterase (AChE) activity in the CSF and brain of patients with Alzheimer"s disease (AD) was investigated in 18 mild AD patients following galantamine treatment. Galantamine 175-186 acetylcholinesterase (Cartwright blood group) Homo sapiens 25-45 17196712-1 2008 The relationship between acetylcholinesterase (AChE) activity in the CSF and brain of patients with Alzheimer"s disease (AD) was investigated in 18 mild AD patients following galantamine treatment. Galantamine 175-186 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-51 17986678-3 2008 The current study was designed to examine the efficacy and safety of galantamine, an acetylcholinesterase inhibitor that also acts as an allosteric modulator at the alpha(4)beta(2) and alpha(7) nicotinic receptors, for the treatment of these impairments. Galantamine 69-80 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-105 18438759-1 2008 Galanthamine, an acetylcholinesterase inhibitor used for the treatment of Alzheimer"s disease, and galanthamine-type alkaloids are synthesised in different plants of the family Amaryllidaceae. Galantamine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-37 18042006-4 2007 This review summarises the current state of the art concerning the pharmacology of galantamine, focusing on the most important details of its possibilities as an acetylcholinesterase inhibitor, an allosteric potentiator of neuronal nicotinic receptors for acetylcholine, a modulator of neurotransmitter release, and an agent causing neuroprotection through an antiapoptotic action. Galantamine 83-94 acetylcholinesterase (Cartwright blood group) Homo sapiens 162-182 17955784-1 2007 The efficacy of the acetylcholinesterase inhibitors donepezil, galantamine and rivastigmine for Alzheimer"s disease is well-documented by a number of studies. Galantamine 63-74 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-40 17374745-0 2007 The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. Galantamine 35-46 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 17656829-2 2007 The mechanism of action that is most generally recognized as underlying the clinical benefits of galantamine is inhibition of brain acetylcholinesterase (AChE). Galantamine 97-108 acetylcholinesterase (Cartwright blood group) Homo sapiens 132-152 17656829-2 2007 The mechanism of action that is most generally recognized as underlying the clinical benefits of galantamine is inhibition of brain acetylcholinesterase (AChE). Galantamine 97-108 acetylcholinesterase (Cartwright blood group) Homo sapiens 154-158 17656829-5 2007 In general, these studies provide evidence of effects beyond those of AChE inhibition alone, most notably in comparisons with other AChE inhibitors, in which galantamine produced similar or greater effects at doses that provided lower levels of brain AChE inhibition. Galantamine 158-169 acetylcholinesterase (Cartwright blood group) Homo sapiens 132-136 17656829-5 2007 In general, these studies provide evidence of effects beyond those of AChE inhibition alone, most notably in comparisons with other AChE inhibitors, in which galantamine produced similar or greater effects at doses that provided lower levels of brain AChE inhibition. Galantamine 158-169 acetylcholinesterase (Cartwright blood group) Homo sapiens 132-136 17374745-5 2007 We wanted to investigate the antipsychotic potential of the AChE inhibitor galantamine, which also allosterically potentiates nicotinic receptor stimulation. Galantamine 75-86 acetylcholinesterase (Cartwright blood group) Homo sapiens 60-64 16601783-1 2005 Galantamine (GAL) is a selective, competitive and reversible acetylcholinesterase (AChE) inhibitor, which increases the activity of the cholinergic system and hence gives rise to an improvement of cognitive functions in patients suffering from dementia of Alzheimer type. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-81 17724973-2 2007 Presently three AChE inhibitors are approved for the treatment of mild to moderately severe Alzheimer dementia: donepezil, rivastigmine and galantamine. Galantamine 140-151 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-20 17425139-1 2007 A simple, rapid, sensitive, and selective liquid chromatography-tandem mass spectrometry method is developed and validated for the quantitation of galantamine, an acetylcholinesterase inhibitor in human plasma, using a commercially available compound, loratadine, as the internal standard. Galantamine 147-158 acetylcholinesterase (Cartwright blood group) Homo sapiens 163-183 17190371-2 2006 Galantamine is an acetylcholinesterase inhibitor that increases the effect of acetylcholine (ACh). Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 16483771-3 2006 AChE inhibitory activity of related monomeric 1-benzylisoquinolines was examined by using Ellman colorimetric assay with galanthamine as a reference standard. Galantamine 121-133 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 17085051-2 2007 Several secolycorine derivatives showed potent inhibitory activity against acetylcholinesterase with the IC(50) value at micromolar range and are more potent than galanthamine. Galantamine 163-175 acetylcholinesterase (Cartwright blood group) Homo sapiens 75-95 16298243-3 2006 We hypothesized that cholinergic malfunction may underlie memory impairment in these subjects and applied a low dosage of an acetylcholinesterase inhibitor and modulator of nicotinic acetylcholine receptors, galantamine (4 mg bid), for 7 days. Galantamine 208-219 acetylcholinesterase (Cartwright blood group) Homo sapiens 125-145 18221196-5 2006 Galanthamine is a long-acting, selective, reversible and competitive AChE inhibitor that has recently been tested in AD patients and found to be readily absorbed, to be a performance enhancer on memory tests in some patients, and to be well tolerated, although some cholinergic side effects were observed. Galantamine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 69-73 16601783-1 2005 Galantamine (GAL) is a selective, competitive and reversible acetylcholinesterase (AChE) inhibitor, which increases the activity of the cholinergic system and hence gives rise to an improvement of cognitive functions in patients suffering from dementia of Alzheimer type. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-87 16601783-1 2005 Galantamine (GAL) is a selective, competitive and reversible acetylcholinesterase (AChE) inhibitor, which increases the activity of the cholinergic system and hence gives rise to an improvement of cognitive functions in patients suffering from dementia of Alzheimer type. Galantamine 13-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-81 16601783-1 2005 Galantamine (GAL) is a selective, competitive and reversible acetylcholinesterase (AChE) inhibitor, which increases the activity of the cholinergic system and hence gives rise to an improvement of cognitive functions in patients suffering from dementia of Alzheimer type. Galantamine 13-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-87 15818530-2 2005 We investigate the cost-effectiveness of the AChE inhibitor Galantamine for patients with Alzheimer"s disease (AD) in a German context. Galantamine 60-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 45-49 16144975-0 2005 Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. Galantamine 72-83 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 16144975-1 2005 Donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (AChE)-inhibiting activity that are currently being used to treat patients suffering from Alzheimer"s disease. Galantamine 29-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-82 16144975-1 2005 Donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (AChE)-inhibiting activity that are currently being used to treat patients suffering from Alzheimer"s disease. Galantamine 29-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 15951032-1 2005 Clinical trials show beneficial effects of acetylcholinesterase (AChE) inhibitors, including galantamine, on cognitive functions in patients with mild to moderate Alzheimer"s disease. Galantamine 93-104 acetylcholinesterase (Cartwright blood group) Homo sapiens 65-69 15818530-5 2005 RESULTS: In the base case, the application of the AChE inhibitor Galantamine is a dominant scenario with cost savings along with gained quality adjusted life years. Galantamine 65-76 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-54 15304241-1 2004 The therapeutic approach for improving the cognitive function in patients with Alzheimer"s disease (AD) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (AChE) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials. Galantamine 294-305 acetylcholinesterase (Cartwright blood group) Homo sapiens 213-233 15304241-1 2004 The therapeutic approach for improving the cognitive function in patients with Alzheimer"s disease (AD) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (AChE) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials. Galantamine 294-305 acetylcholinesterase (Cartwright blood group) Homo sapiens 235-239 15222774-4 2004 Post-hoc analyses of rivastigmine and galantamine in patients with more advanced Alzheimer"s disease have supported the hypothesis that acetylcholinesterase inhibitors are likely be efficacious in this subgroup. Galantamine 38-49 acetylcholinesterase (Cartwright blood group) Homo sapiens 136-156 15380373-0 2004 Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase. Galantamine 21-32 acetylcholinesterase (Cartwright blood group) Homo sapiens 138-158 15296356-0 2004 [Galantamine, an acetylcholinesterase inhibitor with various actions]. Galantamine 1-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-37 15544502-3 2004 Effectiveness in AChE inhibition and side-effect issues of clinical (tacrine, donepezil, galanthamine and rivastigmine) as well as of novel inhibitors is reviewed here. Galantamine 89-101 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-21 15544504-4 2004 In this review we will describe the development of dimeric AChE inhibitors, from the early observations of high inhibition potency by bis-quaternary inhibitors, to the structure-based design of dimers based on tacrine, huperzine A, galanthamine, and polyamines. Galantamine 232-244 acetylcholinesterase (Cartwright blood group) Homo sapiens 59-63 15544507-2 2004 Thus, it is not surprising that the first therapeutic target that has demonstrated therapeutic efficacy on cognition, behaviour and functional daily activities has been the inhibitors of acetylcholinesterase (AChE), i.e. tacrine, donepezil, rivastigmine and galanthamine. Galantamine 258-270 acetylcholinesterase (Cartwright blood group) Homo sapiens 187-207 15544507-2 2004 Thus, it is not surprising that the first therapeutic target that has demonstrated therapeutic efficacy on cognition, behaviour and functional daily activities has been the inhibitors of acetylcholinesterase (AChE), i.e. tacrine, donepezil, rivastigmine and galanthamine. Galantamine 258-270 acetylcholinesterase (Cartwright blood group) Homo sapiens 209-213 15544507-4 2004 For instance, rivastigmine is a dual inhibitor of AChE and butyrylcholinesterase (BuChE), and galanthamine is a mild inhibitor of AChE and an allosteric potentiating ligand of neuronal nicotinic receptors for acetylcholine (nAChRs). Galantamine 94-106 acetylcholinesterase (Cartwright blood group) Homo sapiens 130-134 15132713-4 2004 There is substantial evidence that the cholinesterase inhibitors, including donepezil, galantamine and rivastigmine, decrease acetylcholinesterase activity in a number of brain regions in patients with Alzheimer"s disease. Galantamine 87-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 126-146 14654102-1 2004 Galantamine is currently used to treat Alzheimer"s disease patients; it behaves as a mild blocker of acetylcholinesterase (AChE) and has an allosteric modulating action on nicotinic acetylcholine receptors (nAChRs). Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 101-121 15101572-1 2004 We present the case of a patient with Huntington"s disease and psychosis, whose motor and psychiatric symptoms improved after administration of galantamine, an acetylcholinesterase inhibitor. Galantamine 144-155 acetylcholinesterase (Cartwright blood group) Homo sapiens 160-180 14654102-1 2004 Galantamine is currently used to treat Alzheimer"s disease patients; it behaves as a mild blocker of acetylcholinesterase (AChE) and has an allosteric modulating action on nicotinic acetylcholine receptors (nAChRs). Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 123-127 15088511-2 2003 The approach to the treatment of Alzheimer"s dementia has been greatly modified by the acetylcholinesterase inhibitor drugs, first donepezil (Aricept) and then rivastigmine (Exelon) and galantamine (Reminyl), and the ever-increasing number of demented people forces us to be familiar with their use. Galantamine 199-206 acetylcholinesterase (Cartwright blood group) Homo sapiens 87-107 12742124-1 2003 Galantamine is an acetylcholinesterase inhibitor, recently approved for the treatment of mild-to-moderate Alzheimer"s disease. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 18-38 24944370-1 2003 BACKGROUND: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer"s disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. Galantamine 176-187 acetylcholinesterase (Cartwright blood group) Homo sapiens 134-138 24944370-1 2003 BACKGROUND: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer"s disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. Galantamine 176-187 acetylcholinesterase (Cartwright blood group) Homo sapiens 202-206 14594523-3 2003 All patients were treated with galantamine that may enhance cholinergic function in the brain by inhibiting acetylcholinesterase and potentiating the effects of acetylcholine at nicotinic acetylcholine receptors. Galantamine 31-42 acetylcholinesterase (Cartwright blood group) Homo sapiens 108-128 12635450-3 2003 Galantamine acts both as a reversible competitive inhibitor of acetylcholinesterase (AChE) and as an allosteric modulator of nicotinic acetylcholine receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-83 12635450-3 2003 Galantamine acts both as a reversible competitive inhibitor of acetylcholinesterase (AChE) and as an allosteric modulator of nicotinic acetylcholine receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-89 12635450-11 2003 Galantamine provides the clinician with another choice of an AChE inhibitor for use in treating AD. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-65 14535624-3 2003 The most selective AChE inhibitors, in decreasing sequence, were in order: TAK-147, donepezil and galantamine. Galantamine 98-109 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-23 14535624-6 2003 Among these inhibitors, tacrine, bis-tacrine, TAK-147, metrifonate and galantamine inhibited both the G1 and G4 AChE forms equally well. Galantamine 71-82 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-116 14674789-7 2003 Galantamine works by inhibiting acetylcholinesterase and by allosterically modulating nicotinic receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 32-52 12481195-5 2002 Galantamine modestly inhibits acetylcholinesterase and has an allosteric potentiating ligand effect at nicotinic receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 30-50 12450245-4 2002 More recent investigations have assessed acetylcholinesterase (AChE) and cholinesterase (ChE) inhibitors such as donepezil, rivastigmine and galantamine. Galantamine 141-152 acetylcholinesterase (Cartwright blood group) Homo sapiens 41-61 12548360-3 2002 AChE activity in CSF was significantly increased after treatment with donepezil and galantamine; the opposite was observed in the rivastigmine-treated group. Galantamine 84-95 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 12140604-0 2002 Galanthamine as bis-functional ligand for the acetylcholinesterase. Galantamine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-66 12162759-10 2002 Tacrine and rivastigmine inhibit both enzymes, whereas donepezil and galantamine specifically inhibit AChE. Galantamine 69-80 acetylcholinesterase (Cartwright blood group) Homo sapiens 102-106 12417371-5 2002 Galantamine is both a moderate, reversible, competitive acetylcholinesterase inhibitor, and an allosteric modulator of nAChR. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 56-76 12410061-2 2002 Galantamine is an inhibitor of acetylcholinesterase and a positive allosteric modulator of nicotinic cholinergic receptors (with a FDA-approved indication for the treatment of patients with mild to moderate Alzheimer disease (AD) under the trade name Reminyl). Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 31-51 12410061-7 2002 Galantamine is distinguished from other acetylcholinesterase inhibitors by its positive allosteric modulatory properties, improving the efficiency of transduction of the acetylcholine signal at nicotinic receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 12139365-4 2002 The dual acetylcholinesterase/butyrylcholinesterase (AChE/BuChE) inhibitor rivastigmine was shown to have several potential advantages over the AChE-selective inhibitors donepezil and galantamine for the treatment of BPSD. Galantamine 184-195 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-57 12134305-7 2002 The last approved has been galantamine that in spite of being a modest inhibitor of acetylcholinesterase, improves memory (ADAS cog test) and slows down cognitive impairment of Alzheimer patients. Galantamine 27-38 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-104 19811027-3 2001 In vitro and in vivo studies have confirmed that galantamine is an orally-active, reversible, competitive inhibitor of brain cholinesterase, which is 50 times more selective for acetylcholinesterase, compared with butyrylcholinesterase. Galantamine 49-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 178-198 12031351-2 2002 Only monomeric acetylcholinesterase, a form of acetylcholinesterase dominant in development, increased neurite outgrowth (3-10 U/ml); moreover this effect was not blocked by active site blockers (echothiophate and galanthamine) but was sensitive to the addition of peripheral site blockers (fasciculin and BW284c51). Galantamine 214-226 acetylcholinesterase (Cartwright blood group) Homo sapiens 15-35 12031351-2 2002 Only monomeric acetylcholinesterase, a form of acetylcholinesterase dominant in development, increased neurite outgrowth (3-10 U/ml); moreover this effect was not blocked by active site blockers (echothiophate and galanthamine) but was sensitive to the addition of peripheral site blockers (fasciculin and BW284c51). Galantamine 214-226 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-67 11825333-1 2001 Galantamine is a newly available cholinergic drug that offsets reductions in central cholinergic neurotransmission in Alzheimer"s disease (AD) by specifically and reversibly inhibiting acetylcholinesterase (AChE) and by allosterically modulating nicotinic cholinergic receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 185-205 11825333-1 2001 Galantamine is a newly available cholinergic drug that offsets reductions in central cholinergic neurotransmission in Alzheimer"s disease (AD) by specifically and reversibly inhibiting acetylcholinesterase (AChE) and by allosterically modulating nicotinic cholinergic receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 207-211 11571763-2 2001 BACKGROUND: Galantamine is a reversible, competitive, selective inhibitor of acetylcholinesterase (AChE) that also allosterically modulates nicotinic acetylcholine receptors. Galantamine 12-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-103 19811047-3 2001 The three new acetylcholinesterase inhibitors licensed to treat Alzheimer"s disease (donepezil, rivastigmine and galantamine) have provided clinicians with a major impetus to their desire to diagnose and treat this lethal disease. Galantamine 113-124 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 11669505-10 2001 In addition to increasing nAChR activity, galantamine also inhibits AChE. Galantamine 42-53 acetylcholinesterase (Cartwright blood group) Homo sapiens 68-72 11669505-11 2001 This novel, dual mechanism of action distinguishes galantamine from many other AChE inhibitors. Galantamine 51-62 acetylcholinesterase (Cartwright blood group) Homo sapiens 79-83 11669506-6 2001 Galantamine appears to be novel among marketed agents in that it inhibits AChE and modulates cholinergic nicotinic receptors, perhaps increasing neurotransmission via both mechanisms. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-78 11226635-3 2001 However, CSF-AChE was significantly increased after treatment of AD patients with AChE inhibitors (donepezil and galantamine). Galantamine 113-124 acetylcholinesterase (Cartwright blood group) Homo sapiens 13-17 11396871-1 2001 Galantamine, the most recently approved acetylcholinesterase inhibitor (AChEI) for use in the United States, has allosteric modulating activity at nicotinic receptors and inhibits acetylcholinesterase. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 11230880-2 2001 Galantamine is a novel treatment for Alzheimer"s disease that inhibits acetylcholinesterase and modulates nicotinic receptors. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 71-91 11396871-1 2001 Galantamine, the most recently approved acetylcholinesterase inhibitor (AChEI) for use in the United States, has allosteric modulating activity at nicotinic receptors and inhibits acetylcholinesterase. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 180-200 11449566-3 2001 Herein, we correctly predict the orientation and conformation of the galanthamine molecule in the active site of AChE from Torpedo californica (TcAChE) using a combination of rigid docking and flexible geometry optimization with a molecular mechanics force field. Galantamine 69-81 acetylcholinesterase (Cartwright blood group) Homo sapiens 113-117 11129124-2 2000 Galantamine is a reversible, competitive, tertiary alkaloid AChE inhibitor. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 60-64 11129124-4 2000 In addition to inhibition of AChE galantamine interacts allosterically with nicotinic acetylcholine receptors to potentiate the action of agonists at these receptors. Galantamine 34-45 acetylcholinesterase (Cartwright blood group) Homo sapiens 29-33 11078030-1 2000 Three new cholinesterase inhibitors, donepezil, rivastigmine, and galantamine, all inhibit the enzyme AChE. Galantamine 66-77 acetylcholinesterase (Cartwright blood group) Homo sapiens 102-106 10634129-8 1999 To inhibit cholinesterases, O-demethylgalanthamine was 10-fold more selective for acetylcholinesterase (AChE) versus butyrylcholinesterase (BuChE) than galanthamine. Galantamine 38-50 acetylcholinesterase (Cartwright blood group) Homo sapiens 82-102 10971047-13 2000 As well as modulating nAChR, galantamine inhib- its AChE. Galantamine 29-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 52-56 10971047-15 2000 However, galantamine maintains patients" level of cognitive and daily function for at least 1 year, which has not been reported for other AChE inhibitors. Galantamine 9-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 138-142 10971048-1 2000 Galantamine, a novel treatment for Alzheimer"s disease (AD), has a dual mechanism of action, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 205-225 10971049-5 2000 Galantamine is a new treatment for AD that combines modulation of nicotinic receptors with inhibition of acetylcholinesterase. Galantamine 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 105-125 10762042-2 2000 Compounds 6b-c were found to be more potent than galanthamine and tacrine in inhibiting AChE. Galantamine 49-61 acetylcholinesterase (Cartwright blood group) Homo sapiens 88-92 10749487-4 2000 The detection limit of galanthamine, an AChE inhibitor, in the HPLC-biochemical detection is 0.3 nmol. Galantamine 23-35 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-44 11261808-2 2000 Originally established as a reversible inhibitor of the acetylcholine-degrading enzyme acetylcholinesterase (AChE), galantamine also acts as an allosterically potentiating ligand (APL) on nicotinic acetylcholine receptors (nAChR). Galantamine 116-127 acetylcholinesterase (Cartwright blood group) Homo sapiens 109-113 10634129-8 1999 To inhibit cholinesterases, O-demethylgalanthamine was 10-fold more selective for acetylcholinesterase (AChE) versus butyrylcholinesterase (BuChE) than galanthamine. Galantamine 38-50 acetylcholinesterase (Cartwright blood group) Homo sapiens 104-108 9839013-0 1998 Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. Galantamine 130-142 acetylcholinesterase (Cartwright blood group) Homo sapiens 7-27 9839013-1 1998 New galanthamine derivatives, especially bis-interacting ligands 3-5 and 7-9 were prepared in order to interact with the catalytic and the peripheral sites of acetylcholinesterase (AChE). Galantamine 4-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 159-179 9839013-1 1998 New galanthamine derivatives, especially bis-interacting ligands 3-5 and 7-9 were prepared in order to interact with the catalytic and the peripheral sites of acetylcholinesterase (AChE). Galantamine 4-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 181-185 9839013-3 1998 Compounds 4d-e were found to be more potent than galanthamine and tacrine in inhibiting AChE. Galantamine 49-61 acetylcholinesterase (Cartwright blood group) Homo sapiens 88-92